Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDAGlobeNewsWire · 1 day ago
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026GlobeNewsWire · 5 days ago
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingGlobeNewsWire · Oct 8, 2026
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERDGlobeNewsWire · Sep 29, 2026
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?Defense World · Sep 17, 2026
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS LawGuruFocus · Sep 16, 2026Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.18 | -$0.21 | Miss |
| Apr 30, 2026 | -$0.27 | -$0.37 | Miss |
| Feb 26, 2026 | -$0.32 | -$0.29 | Beat |
| Oct 30, 2025 | -$0.40 | -$0.41 | Miss |
| Aug 7, 2025 | -$0.76 | -$0.79 | Miss |
| May 1, 2025 | -$1.06 | -$1.07 | Miss |